

RESEARCH ARTICLE

Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures

Dirk Schumacher^{1,2}, Geoffroy Andrieux^{2,3}, Karsten Boehnke⁴, Marlen Keil⁵, Alessandra Silvestri⁶, Maxine Silvestrov⁶, Ulrich Keilholz⁷, Johannes Haybaeck^{8,9,10}, Gerrit Erdmann^{11,12}, Christoph Sachse^{11,12}, Markus Templin^{12,13}, Jens Hoffmann⁵, Melanie Boerries^{2,3}, Reinhold Schäfer^{2,7*}, Christian R. A. Regenbrecht^{6,8,12*}

1 Laboratory of Molecular Tumor Pathology, Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany, **2** German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany, **3** Institute of Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany, **4** Eli Lilly and Company, Lilly Research Laboratories, Oncology Translational Research, New York, NY, United States of America, **5** EPO Experimental Pharmacology and Oncology Berlin-Buch GmbH, Berlin, Germany, **6** cpo—Cellular Phenomics & Oncology Berlin-Buch GmbH, Berlin, Germany, **7** Charité Comprehensive Cancer Center, Berlin, Germany, **8** Department of Pathology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany, **9** Department of Pathology, Neuropathology, and Molecular Pathology, Medical University of Innsbruck, Austria, **10** Diagnostic & Research Center for Molecular BioMedicine, Institute of Pathology, Medical University of Graz, Austria, **11** NMI TT Phasmaservices, Berlin, Germany, **12** ASC Oncology GmbH, Berlin, Germany, **13** NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany

* reinhold.schaefer@charite.de (RS); christian.regenbrecht@asc-oncology.eu (CRAR)



OPEN ACCESS

Citation: Schumacher D, Andrieux G, Boehnke K, Keil M, Silvestri A, Silvestrov M, et al. (2019) Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures. *PLoS Genet* 15(3): e1008076. <https://doi.org/10.1371/journal.pgen.1008076>

Editor: Nicola Valeri, Institute of Cancer Research, UNITED KINGDOM

Received: May 2, 2018

Accepted: March 8, 2019

Published: March 29, 2019

Copyright: © 2019 Schumacher et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files. Sequencing data was deposited at the European Nucleotide Archive (ENA) under study ID PRJEB22058 (<https://www.ebi.ac.uk/ena/data/view/PRJEB22058>).

Funding: This work was funded by the Innovative Medicine Initiative (IMI) under grant agreement no. 115234 (European Union's Seventh Framework Program FP7/2007-2013; 'OncoTrack'), the European Fonds for Regional Development (EFRE),

Abstract

Organoid cultures derived from colorectal cancer (CRC) samples are increasingly used as preclinical models for studying tumor biology and the effects of targeted therapies under conditions capturing *in vitro* the genetic make-up of heterogeneous and even individual neoplasms. While 3D cultures are initiated from surgical specimens comprising multiple cell populations, the impact of tumor heterogeneity on drug effects in organoid cultures has not been addressed systematically. Here we have used a cohort of well-characterized CRC organoids to study the influence of tumor heterogeneity on the activity of the KRAS/MAPK-signaling pathway and the consequences of treatment by inhibitors targeting EGFR and downstream effectors. MAPK signaling, analyzed by targeted proteomics, shows unexpected heterogeneity irrespective of *RAS* mutations and is associated with variable responses to EGFR inhibition. In addition, we obtained evidence for intratumoral heterogeneity in drug response among parallel "sibling" 3D cultures established from a single *KRAS*-mutant CRC. Our results imply that separate testing of drug effects in multiple subpopulations may help to elucidate molecular correlates of tumor heterogeneity and to improve therapy response prediction in patients.

a grant from the German Cancer Consortium (DKTK) to R.S. and a Berlin Cancer Society grant to C.R.A.R. (BKG, REF201402). M.B. was supported by the Deutsche Forschungsgemeinschaft (DFG) CRC850 for the project Z1/C9 and by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (coNfirm, FKZ 01ZX1708F). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: R.S., J.H. and C.R.A.R. are founders of CPO, a start-up company in the field of chemosensitivity testing. C.S., M.T. and G.E. are employees of NMI and NMI TT Pharmservices, which provide DigiWest analysis. We declare that none of the companies financed any part of the study nor interfered with the analyses and/or interpretation of data. Publishing this manuscript does not lead to any financial benefit to authors.

Author summary

Commonly occurring genetic alterations and patient-specific genetic features are increasingly used to predict the possible action of targeted cancer therapies. Although several lines of evidence have suggested that preclinical and clinical responses concur, the heterogeneity of tumors remains a severe obstacle in routinely translating preclinical data to patient treatments. Here we present a rapid work flow that integrates drug testing of three-dimensional patient tumor-derived (organoid) cultures and assessment of their genetic make-up as well as that of their donor tumors by amplicon sequencing and targeted proteomics. While the organoid cultures largely recapitulated the genomic profiles of donor tumors, the overall treatment responses and inhibitor effects on the intracellular signaling system were quite variable. Notably, organoid cultures obtained by synchronous multi-regional sampling of the same colorectal tumor showed an up to 30-fold difference in drug response. A combinatorial drug treatment improved the response. These data were confirmed in matched mouse xenograft models from the same tumor. Our findings may help to refine preclinical testing of individual tumors by modelling heterogeneity in cultures, to better understand therapeutic failure in clinical settings and to find ways to overcome treatment resistance.

Introduction

Colorectal cancer (CRC) is the third most common cancer worldwide. The major molecular alterations driving cancer of the colonic epithelium involve dysfunction of the WNT/APC and KRAS/MAPK pathways, DNA repair and methylation, and chromosomal instability [1, 2]. Concerted analysis of colorectal cancer transcriptomes has identified consensus molecular subtypes (CMS) that comprise genes controlling cell-type-specific functions, signaling pathways, and, in part, prognosis-relevant characteristics [3, 4]. CMS1 features genes involved in hyper-mutation and hyper-methylation. CMS2 represents the properties of epithelial tumor characteristics mainly driven by WNT/MYC signaling. CMS3 characterizes *KRAS*-mutated CRC and reflects genes controlling metabolic pathways. CMS4 exhibits expression of stromal components and activation of TGF-beta and VEGFR pathways. Like in other cancer entities, the administration of targeted drugs to colorectal cancer patients is based on the molecular profile of their tumors. Mutations in *RAS* gene family members or *BRAF* turn out to be negative predictors for anti-receptor tyrosine kinase therapies [5], while at least a subset of *RAS* wild-type tumors shows a therapeutic response [6].

Three-dimensional cell culture systems provide accurate and physiologically relevant models for studying the biology of diseases, and they support clinical research as well as drug development [7]. Recently, several groups have described patient-derived colorectal cancer organoids as a discovery platform for therapeutics and for validating the predicted impact of molecular features on therapy responses. Since the tissue architecture, tumor cell-specific genomic alterations, and consensus molecular signatures are essentially maintained in organoid cultures, these models are an excellent source for studying tumor biology in general under conditions reflecting clinically manifested heterogeneities of mutational patterns and epigenetic alterations [8–12]. For example, we identified the hedgehog pathway as a critical driver of colon cancer stem cell survival and tumorigenesis [13]. In scenarios approximating clinical behavior, drug treatments of CRC organoid cultures can even be used to predict personalized therapeutic options for individual patients [10]. A recent report has indeed documented the close relationship between drug effects observed in patient-tumor-specific

organoid cultures and clinical responses in donor patients enrolled in clinical trials [14]. CRC organoid cultures also recapitulated the clinically well-known resistance of *KRAS*-mutant cells toward anti-receptor kinase therapies and showed limited effects of combinatorial targeted therapies against *KRAS* pathway effectors [15].

It is well known that the molecular diagnosis of primary and metastatic tumors, typically based on single biopsies representing snapshots of ongoing tumor evolution, may be compromised by intratumor heterogeneity (ITH) [16, 17]. Multi-region sampling of solid tumors revealed substantial ITH, as indicated by diverse patterns of cancer gene mutations [18] and copy number alterations [19] in different tumor areas. Individual tumors may harbor up to 10 or more preexisting subpopulations. Tumor evolution is assumed to be based on multiple initial alterations [20], and spatially separated subpopulations of cancer cells are generated during tumor progression [21]. Therefore, ITH is very likely to significantly influence initiation, establishment, fitness, and molecular characteristics of patient-tumor-derived organoid cultures.

Here, we used a previously characterized set of CRC organoids [11], supplemented by novel models, to investigate the impact of intertumor and intratumor heterogeneity on drug response. We chose to analyze the mutation status of the organoids by targeted amplicon sequencing, because interrogating a limited number of driver genes is often used as the standard diagnostic procedure [22, 23]. In addition, we analyzed signaling pathways in a subset of organoid models by targeted proteomics [24]. We correlated mutation patterns and pathway activity with the response to selected compounds targeting receptor tyrosine kinases, the RAS/MAPK, and PIK3CA pathway. Finally, we modelled the consequences of ITH on tumor cell growth and drug response in independently generated “sibling” cultures from the same donor tumor *in vitro* and *in vivo*.

Results

Establishment and molecular characterization of patient CRC-derived organoid cultures

Currently, our collection of patient-tumor-derived cell culture models comprises 91 organoids originating from 158 primary or metastatic tumor specimens (S1 Table). Due to the limitations of clinical material, not all tumor biopsies obtained gave rise to proliferation-competent organoid cultures. The time intervals required for the first transfer of primary to secondary cultures varied substantially but was not related to the UICC stage of donor tumors (Fig 1A, S1 Fig). Sufficient cell material for subsequent assays was available in 70% (51/71) of cultures 3 to 4 weeks post-explantation, while the remaining cultures required 5 to 12 weeks. Successfully established cultures maintained typical CRC marker expression and an adenoma-like architecture that retains higher-order organization and apical-basal polarity of the colonic epithelium, as reported earlier [11]. In view of the reported genomic heterogeneity of CRCs, the cultures were expected to be invariably polyclonal during establishment and early passaging.

We evaluated 50 cancer genes by ultra-deep targeted amplicon sequencing [25] in 49 organoids and 29 matched donor tumors (Fig 1B, S2 Table). Donor tumors and derived models both harbored common driver mutations in *EGFR/RAS/RAF/MEK*, *PIK3CA/AKT*, and *TGF-beta* signaling pathways, confirming previous exome sequencing results [11]. There were few exceptions, most likely due to population dynamics in the original tumor tissues [11, 18, 19]. Donor tumor tissue OT288 harbored an *ABL1* mutation at a frequency of 6.3%, not detected in the corresponding organoid culture. The *SMAD4* and *PIK3CA* mutations manifested in OT159 and OT161 cultures were not detected in the donor materials. A low-frequency *APC* mutation in tumor OT281, represented by only 3% of sequencing reads, was retrieved as a




Fig 1. PD3D culture generation statistics and genomic analysis. (A) Duration (weeks) from culture initiation to first passage (primary tumors n = 54; metastatic tumors n = 17). UICC stages are indicated in the grey scale; metastases are generally considered as stage IV. (B) Mutation of key genes affected in CRC found via cancer gene panel sequencing in 49 patient-derived three-dimensional (PD3D) cultures and 29 matched original tumor samples (indicated with a black box at the bottom). The percentage of organoid cultures harboring a mutation in a given gene is shown on the left side, the overall

number of mutations per gene is given on the right as a bar chart. Microsatellite instability was found in 3 of 43 tested samples (7%), indicated by a black box below the matrix. (C) For sequenced organoid cultures, duration of culturing until the first passages correlated with critical mutations. Color code is given in the figure (wt = no mutations in MAPK/PI3K-AKT/TGF β -SMAD4 pathways).

<https://doi.org/10.1371/journal.pgen.1008076.g001>

homozygous mutation in the corresponding organoid culture. As the received samples represented a macro-dissected admixture of tumor cells and adjacent healthy cells of different cell types, increased mutation frequencies *in vitro* were most likely due to enrichment of tumor cells by the used culture system and medium.

Notably, we observed a trend for earlier passaging in cultures that had accumulated mutations in *RAS*, *PI3K/AKT*, or *SMAD4*, as indicated by robust establishment and short culture intervals (Fig 1C).

***In vitro* drug response of organoid cultures is heterogeneous and independent of their *KRAS* oncogene status and pathway activation**

For anti-EGFR treatment testing of 38 *KRAS*-mutant and wild-type organoid cultures, we focused on the small molecules gefitinib, afatinib, and sapitinib (Fig 2A–2C, S3 and S4 Tables) rather than on the monoclonal antibody cetuximab because its effects in cell culture do not correlate well with clinical action. Earlier reports described IC₅₀ values for cetuximab in the millimolar range, either directly measured or extrapolated [9, 26, 27], while biologically relevant concentrations were reported to be in the nanomolar range [28]. In addition to preventing the binding of ligand to its receptor, cetuximab exerts antibody-derived cellular cytotoxicity, not recapitulated well under cell culture conditions [29, 30].

We considered potentially relevant inhibitory effects of the compounds at a range of concentrations achievable in patient plasma—i.e., at or close to the c_{ss} steady-state concentration (Fig 2, grey areas) that reduced viability of >50% of cells under the testing conditions. The IC₅₀ values for gefitinib ranged from 0.12 μ M to >60 μ M. Thirty-one of 38 cultures were resistant to gefitinib, including 13 quadruple-negative cultures (*KRAS*^{wt}, *NRAS*^{wt}, *BRAF*^{wt}, and *PIK3CA*^{wt}) and 16 cultures harboring mutations in at least one of these critical genes. Four quadruple-negative, two *PIK3CA*-mutant, and one exceptional *BRAF*^{V600E}-mutant cultures responded to gefitinib treatment. The resistance to receptor tyrosine kinase inhibitors corroborated previous preclinical and clinical findings [4], although the range of growth responses indicated substantial heterogeneity of cultures regardless of critical driver mutations. The IC₅₀ values for afatinib and sapitinib ranged from 0.025 μ M to 11.7 μ M and from 0.033 μ M to >60 μ M, respectively. In total, 34 cultures did not respond to afatinib, and 25 did not respond to sapitinib.

In view of the heterogeneous drug response, we added another layer of molecular information to the models by contrasting protein profiles of nine organoid cultures, matched tumor tissues, and morphologically normal tissues adjacent to the tumors (S2 Fig, S5 Table). We applied the novel DigiWest bead-based western blot method, designed for in-depth protein profiling of cellular signal transduction [24]. Overall, protein and phosphoprotein abundance varied substantially among cultures and tissues. Next, we correlated the drug response with the activation status of the MAPK pathway (Fig 3). Surprisingly, gefitinib-resistant cultures OT227 (*KRAS*^{G13D}), OT209-M (*KRAS*^{G12V}), OT161 (*KRAS*^{G12S}), and OT151 (*NRAS*^{Q61K}) exhibited very diverse pathway activation, ranging from throughout high expression of p-ERK1, p-ERK2, and pRSK1, for example, to low expression and phosphorylation, respectively. Expression of DUSP6, an antagonist of MAPK signaling involved in feedback regulation, was not consistently associated with diminished phosphorylation of signaling kinases. We




Fig 2. *In vitro* drug response waterfall plots of 38 organoid cultures show individual patterns of resistance and sensitivity. IC₅₀ values for 38 *in vitro* models were determined with a semi-automated drug response assay platform. The lower and upper assay cutoffs were 0.003 μM and 60 μM. Drug efficacy (E_{max}) was included as additional measure of response, indicated with light grey to black boxes according to percent efficacy above the waterfall plot. The genotype of each culture according to panel sequencing is color-coded according to the legend given at the bottom of the figure. Area (grey) of achievable steady state *in vivo* plasma concentrations (c_{ss}) are given in μM and indicated with grey dotted lines. (A-C) IC₅₀ values for small molecules gefitinib, afatinib and sunitinib, targeting the ERBB receptor(s) ERBB1/EGFR, ERBB2/Her2, ERBB3 and ERBB4. (D) Inhibition at the level of MEK1/2 with selumetinib. (E) Response to the multikinase inhibitor regorafenib. (F) Treatment with the mTORC1/2 inhibitor BI-860585. The BRAF^{G466R} and BRAF^{G466V} mutations in tumors OT170 and OT327, respectively, are not included in the figure, as their gene products are considered kinase-dead [77].

<https://doi.org/10.1371/journal.pgen.1008076.g002>




Fig 3. Bead-based western blot analysis of (phospho-)proteins in 9 organoid cultures. DigiWest-based protein expression analysis of 30 (phospho-) proteins in 9 PD3D cultures is shown together with genotype and response data. Samples are sorted according to RAS mutation status. Individual IC_{50} values are shown for tested compounds. Green marked IC_{50} 's indicate susceptibility to the respective small molecule. Protein expression values are column-wise color-coded from lowest (yellow) to highest (blue) expression for each analyte. Phosphoproteins are marked in grey.

<https://doi.org/10.1371/journal.pgen.1008076.g003>

observed a similarly diverse pattern of pathway activation in gefitinib-responsive RAS^{wt} organoids OT299 and OT276 and the resistant cultures OT347-M01 and OT278.

In addition to blocking receptor tyrosine kinase activity, we treated organoid cultures with the MEK inhibitor selumetinib, the multi-kinase inhibitor regorafenib, and a novel mTORC1/2 inhibitor BI-860585 [31] (Fig 2D–2F, S3 and S4 Tables). We found resistance to selumetinib in 16 out of 17 quadruple-negative organoids and in 13 out of 16 RAS -mutated ones. Three $PIK3CA$ -mutated, RAS^{wt} organoid cultures were equally resistant, while the $BRAF^{V600E}$ cultures OT261 and OT212 were sensitive. This finding would suggest that in the absence of damaging RAS and $PIK3CA$ mutations, signaling downstream of BRAF was efficiently blocked. The two $KRAS^{G12D}$ cultures OT302 and OT288 were exceptionally sensitive to MEK inhibition; however, the susceptibility towards the inhibitors was not exclusive for this kind of $KRAS$ mutation.

Treatment with the multi-kinase inhibitor regorafenib that targets CRAF and VEGF receptors resulted in responses irrespective of the mutational status of RAS and $PIK3CA$, with the distribution of sensitive versus resistant cultures being approximately equal for wild-type and mutant cultures (Fig 2E). The range of IC_{50} values in most cultures was relatively narrow (3.05–23.9 μ M), except for cultures OT114 and OT152 (>60 μ M) and OT234 (0.58 μ M). Since regorafenib specifically targets the tumor vasculature, any conclusions regarding the proliferation of organoids are very limited [14].

Nineteen out of 38 organoid cultures responded upon treatment with BI-860585, and 19 were resistant (Fig 2F). All $PIK3CA/PTEN$ -mutant, $KRAS^{wt}$ organoids responded to the mTORC1/2 inhibitor, three $PIK3CA/KRAS$ mutant cultures were resistant, and two of them were sensitive. Analysis of protein extracts by the bead-based western blotting method revealed that neither the level of p85 (alpha), p110 beta or PTEN expression nor the phosphorylation status of PTEN and AKT correlated with the response to mTORC1/2 inhibition (Fig 3).

Next we analyzed the effects of the RTK inhibitors gefitinib, afatinib and sapitinib by profiling 3 selected organoids OT151, OT276 and OT347-M01 employing DigiWest protein expression profiling after drug exposure for 72h. To avoid substantial cell loss and accumulation of

cellular debris during drug exposure, we chose drug concentrations primarily based on the clinically achievable plasma concentrations (c_{ss} , [S3 Table](#)). There were two exceptions, in which the IC_{50} was achieved already below the relevant plasma concentration in patients. Accordingly, we treated OT276 with 0.35 μ M gefitinib and OT347-M01 with 0.20 μ M sapitinib. The detailed results of DigiWest analysis are shown in [S3 Fig](#) and [S6 Table](#). Hierarchical clustering of the analyzed data showed that patient derived organoids formed three separate branches in the dendrogram. These were split further into branches distinguishing gefitinib from afatinib and sapitinib treatment indicating a dominant but distinctive effect of the tested drugs on each individual organoid culture.

For example, the treated *NRAS* mutant organoid OT151 showed an increase in phosphorylation of central proteins of the MAPK signaling cascade, including ERK, RSK, and S6 ribosomal protein ([S3 Fig](#), [S6 Table](#)). While this expression- and activity pattern could easily be reconciled with the resistance to anti-receptor tyrosine kinase inhibition, there was no clear correlation between treatment resistance and drug-modulated signaling patterns in OT276 and OT347-M01 cells. OT276 cells were sensitive to afatinib and sapitinib treatment although p-MEK was increased. Sapitinib sensitivity in OT347-M01 cells was associated with low MAPK activity. We observed a distinct modulation of WNT signaling indicated by GSK3 β phosphorylation and a high increase in active beta-catenin in OT347-M01 cells. MTOR activity appeared to be high in OT276 but low in OT347-M01. Overall, most alterations observed 72h after drug exposure are very likely due to the rewiring of the entire signaling system involving adaptive feed-back and cross-talk mechanisms.

Genetic, transcriptomic, and inhibitor response heterogeneity in multi-sampled cell culture models derived from a single primary tumor

To investigate the impact of ITH on treatment effects in organoid cultures, we analyzed mutational patterns and drug responses of five organoid “sibling” cultures established in parallel from separate regions of an individual primary colon carcinoma (CC0514-R1, -R2, -R3, -R4, and -R5). Tissue architecture, Ki67 expression, and expression patterns of markers routinely used to characterize tumors of the colonic epithelium recapitulate those of the donor tumor ([Fig 4](#)). Using the 50-gene cancer panel, we detected common *KRAS*^{G12D}, *PIK3CA*^{H1047R}, and *TP53*^{C242F} mutations in the tumor tissue-of-origin and the separate sibling cultures, as well as an additional homozygous *SMAD4*^{R361H} mutation in cultures CC0514-R1 and CC0514-R2 ([Fig 1B](#), [S2 Table](#)). This mutation affects the MH2 domain of the protein and abolishes R-SMAD/SMAD4 heterodimerization [32]. All sibling cultures represented the molecular subtype CMS2 ([S7 Table](#)), according to the classification by Guinney and colleagues [3].

First, we assayed drug responses in the sibling cultures using inhibitors targeting EGFR, MEK, ERK, p110 α , and mTORC1/2 as well as sorafenib and regorafenib ([Fig 5A–5C](#), [S4 Table](#)). The drug responses of sibling cultures were not uniform. Organoid culture R1 was unique by being unaffected by inhibitors targeting EGFR, MEK, ERK, PI3K α , and mTORC1/2. In contrast, culture R4 was sensitive toward EGFR, PI3K α , and mTORC1/2 inhibition. The remaining cultures, R2, R3, and R5 shared resistance with R1 to EGFR inhibition, but responded heterogeneously to the other compounds.

As the underlying mutations did not sufficiently explain the observed differences in drug response, we expanded molecular analysis by exome and RNA sequencing. Exome sequencing confirmed the mutations found via panel sequencing. An additional shared heterozygous mutation was found for beta-catenin (*CTNNB1*^{R582W}). The original tumor tissues and sibling cultures exhibited a remarkable genetic heterogeneity ([Fig 6](#)). Unbiased analysis of their somatic mutation landscapes highlighted specific mutations in every single region or derived




Fig 4. Immunohistochemical stainings of “sibling organoids” and original colorectal carcinoma. Immunohistochemical staining with hematoxylin and eosin (HE) and expression of Ki67, CDX2, CK20 and CK7 show overlapping patterns in tumor tissue and derived PD3D cultures R1-R5 of patient CC0514. Scale bars: 200 μ m.

<https://doi.org/10.1371/journal.pgen.1008076.g004>

culture (Fig 6A, S8 Table). Phylogenetic trees of the tumor mutations suggested a grouping of tumor regions and organoids CC0514-R1/R2 versus R3, R4, and R5. Moreover, unbiased principal component analysis (PCA) based on the complete transcriptomes of the cultures showed a high variance between cultures R1/R2 and R3, R4, and R5 (Fig 6B). Overall, we identified 646 differentially expressed genes when contrasting *SMAD4*^{R361H} and *SMAD4*^{wt} cultures (R1 and R2 vs. R3, R4, and R5; adj. $p < 0.05$, logFC >1, S9 Table). We visualized the mRNA transcriptome of sibling cultures in heatmaps, focusing on ERK/MAPK-, PI3K-, and mTOR-signaling pathways (Fig 6C). Although retrieving the same sample dichotomy between the R1/R2 and R3–5 groups, we observed substantial heterogeneity in mRNA expression of target genes encoding components of the respective pathways.

***In vivo* modeling of intratumor heterogeneous cellular expansion and treatment response**

To model the therapy response in a heterogeneous tumor cell population *in vivo*, we first labeled organoid cultures CC0514-R1 and CC0514-R4 by transduction with phosphoglycerate kinase (PGK) promoter-driven expression vectors encoding the fluorescence markers GFP and mCherry (mCh), respectively. We then prepared single-cell suspensions of R1-GFP and R4-mCh cells embedded in Matrigel, separately or as a 1:1 mixture of R1-GFP and R4-mCh cells, injected them subcutaneously into nude mice, and calculated the tumor volumes over time (S10 Table). The R1-GFP cells rapidly formed tumors with a mean volume of 1.36 (± 0.16) cm^3 after 18 days, while the R4-mCh tumor xenografts achieved less than one-tenth of these volumes (mean 0.11 $\text{cm}^3 \pm 0.03$) after the same period. Even at >80 days after inoculation, R4-mCh tumors were smaller (mean volume 0.76 $\text{cm}^3 \pm 0.66$) than R1-GFP tumors that had formed much earlier. The mixed suspensions of R1-GFP and




Fig 5. Organoid sibling cultures display heterogeneous drug responses. IC₅₀ values for sibling cultures derived from patient tumor CC0514 treated with a panel of small molecules targeting EGFR, MEK/ERK, PI3K α , mTORC1/2 and multiple kinases are shown. The lower and upper assay cutoffs were 0.003 μ M and 60 μ M. Drug efficacy (E_{max}) was included as additional parameter of response, indicated with light grey to black boxes above the waterfall plot according to percent efficacy. Critical mutations in each culture are depicted in light and dark grey bars according to the legend at the bottom of the figure. Achievable steady state *in vivo* plasma

concentrations (c_{50}) are given in μM and indicated with grey dotted lines. (A) IC_{50} values found following inhibition at the EGF receptor. (B) IC_{50} values found following inhibition at downstream pathway components MEK and ERK. (C) Inhibition with alpelisib (targeting PI3K α), BI-860585 (mTORC1/2) and the multi-kinase inhibitors sorafenib and regorafenib.

<https://doi.org/10.1371/journal.pgen.1008076.g005>

R4-mCh cells produced tumors after a short lag phase. Tumor volumes comparable to the ones produced only by R1-GFP cells were reached approximately 10 days later (Fig 7A, S10 Table). Notably, the architecture of mixed-culture xenografts indicated strict clonal




Fig 6. Tumor tissues and sibling cultures of patient CC0514 display genetic heterogeneity and heterogeneous mRNA expression profiles. Heterogeneity of tumor tissues and PD3D sibling cultures was evaluated on DNA and mRNA levels. (A) On the genomic level, somatic mutations were called from DNA of the five original tumor pieces (R1-R5) of the primary tumor of patient CC0514 and the respective PD3D sibling cultures, compared to CC0514 patient's blood. Cellular content of tumor tissue R4 was very low. UpSet plots show rare somatic mutations (MAF < 0.001) in exonic regions used to construct evolutionary trees of the somatic mutations, displayed next to the plots. The numbers of shared or private mutations are given. (B) Principal Component Analysis of the mRNA expression of the sibling cultures. First component on x-axis contains 75% of the variance and classifies the samples into two major groups R1/R2 vs. R3/R4/R5). (C) Heatmaps of mRNA expression of components of ERK/MAPK, PI3K and mTOR signaling pathways. Each row has been transformed using Z-score. The color code represents the scaled mRNA expression across samples. Genes and samples were hierarchically clustered using Euclidean distance.

<https://doi.org/10.1371/journal.pgen.1008076.g006>

outgrowth *in vivo*, as the R1-GFP and R4-mCh cells always formed separate organoid structures (Fig 7B).

For targeting the EGFR/RAS/MEK-signaling system *in vivo*, we chose the clinically approved EGFR antibody cetuximab and the MEK inhibitor trametinib (S11 Table). The duration of treatment with individual and combined inhibitors was planned for 36 days, following an initial period of 10 days post-injection to achieve engraftment. However, in cases of rapid tumor establishment and progression, the experiment had to be terminated earlier. After measuring tumor volumes, we sacrificed the mice, dissociated the tumor cells, and determined the ratio of R1-GFP and R4-mCh cells by FACS (S12 Table).

In xenografts derived from mixed cultures, R1-GFP cells formed the dominant population, indicated by its greater potential for expansion (Fig 7C, S10 Table). Compared to inoculation of single-cell suspensions, co-injection of R1-GFP and R4-mCh cells, left untreated or treated with vehicle, retarded the onset of tumor growth slightly, and progression to 1.0 cm³ tumors was apparent after an additional week (Fig 7D). Treatment of the KRAS-mutant mixed cultures with cetuximab or trametinib alone reduced tumor take rate (determined on day 38 post-injection) and substantially prolonged the period required for achieving an equal 1.0 cm³ tumor mass in two out of three tumors (Fig 7E and 7F). At the end of this experiment, the R1-GFP population outnumbered the R4-mCh population in controls and inhibitor-treated tumors. Reduction of tumor takes and volumes was more pronounced following cetuximab/trametinib co-treatment. Moreover, the R4-mCh population outnumbered the R1-GFP population, indicating that the latter population was vulnerable to co-treatment, although a minor fraction of R1-GFP cells survived combination treatment (Fig 7G, S12 Table). The initial response to cetuximab treatment of R1-GFP tumors may be due to a surprisingly low activation level of MAPK signaling; however, antibody-dependent toxicity cannot be excluded (Fig 7H, S5 Table). In contrast, the R4-mCh population exhibited enhanced levels of p-ERK1/2 in spite of its low growth potential *in vivo*. The growth kinetics of R4-mCh organoids *in vivo* suggest that the duration of inhibitor exposure until day 45 post-injection into mice was too short for this slowly expanding population, although *in vitro* testing showed susceptibility to anti-EGFR treatment (Fig 5). The presence of GFP-positive cells beyond day 45 suggested that after initial debulking, this population escaped from treatment by anti-receptor tyrosine kinase antagonists, in-line with the results from *in vitro* testing. The slowly expanding R4-mCh cells may even have provided a niche for surviving R1-GFP cells.

The R1/R4 xenografts responded partially to administration of everolimus, regorafenib, and pictilisib, as well as to combinations of these three drugs with cetuximab (S11 Table). In five out of six experiments, the proportion of residual R1-GFP cells relative to R4-mCh cells after treatment indicated partial response of the rapidly proliferating R1-GFP population and the relative resistance of the R4-mCh population able to increase in number at the expense of R1-GFP cells.

Discussion

Here we show heterogeneous pathway activity and inhibitor responses in CRC organoid cultures profiled by cancer gene panel sequencing and DigiWest-based signaling-pathway analysis. Eight KRAS^{G12V/S/D} cultures were resistant to EGFR inhibition by gefitinib, as were four KRAS^{G13D} and three NRAS^{Q61K} cultures, one KRAS^{A146T} and one BRAF^{V600E} culture. Four quadruple-negative and two RAS wild-type/PIK3CA-mutant cultures responded to gefitinib. Basically, these results are in line with diagnostic and clinical experience regarding the administration of therapeutic antibodies targeting EGFR [4] and a recent report on colorectal cancer organoids [15]. In our cohort, 12 quadruple-negative cultures were resistant to gefitinib




Fig 7. Subpopulation-specific response to *in vivo* drug treatment. (A) Cells of sibling cultures CC0514-R1 and CC0514-R4 were transduced with PKF-GFP and PGK-mCherry (mCh) markers, respectively. 1.0×10^6 cells were injected into nude mice either as single populations (green/red) or as a 1:1 mixture of both populations (grey) in triplicate. (B) Microscopic images of a mixed

R1-PGK-GFP and R4-PGK-mCherry tumor, scale bars: 200 μ m. (C) Mixed populations of R1 and R4 cultures were subjected to treatment *in vivo* in triplicate. Treatments started 10 days post injection included 5 single compounds and combinations with cetuximab. Treatments were carried out until 45 days (dashed line), if possible. PDX tumors showing minor growth post treatment were maintained *in vivo* to monitor subsequent growth. The bubble plot shows tumor sizes, as represented by bubble diameter, and fold enrichment of cell subpopulations for all replicates in treatment groups A-J (displayed in the figure). Green (= GFP⁺) or red (mCherry⁺ = mCh⁺) fills indicate which subpopulation was more abundant in the PDX tumor, as measured by FACS analysis of re-suspended tumor cells. Grey circles indicate a 50:50 distribution of labelled tumors. Note that for PDX tumors C2 and E2 both fold enrichment and tumor size were at a similar range (S11 and S12 Tables). (D-G) Tumor growth kinetics during the course of the *in vivo* mixing experiment are shown together with the fractions of GFP⁺ and mCh⁺ populations at the end of the experiment (FACS analysis). Treatments were done with vehicle, trametinib, cetuximab and cetuximab+trametinib combination. (H) Protein expression of CC0514-R1-GFP and CC0514-R4-mCh organoids analyzed by DigiWest protein assay. Difference in fold expression ranging from 1.5 (yellow) to 5.3 (blue).

<https://doi.org/10.1371/journal.pgen.1008076.g007>

treatment. The magnitude of drug resistance observed in quadruple-negative cultures is reminiscent of clinical experience in tumor treatment. For example, the organoid culture OT330 and its donor tumor harbored an *ERBB2* amplification [11]. High *ERBB2* expression detected *in vitro* is known to cause resistance to EGFR-targeting compounds [33, 34]. Moreover, OT330 shared increased levels of MET mRNA with the *KRAS*^{wt} cultures OT216 and OT281. High MET expression in the absence of activating *KRAS* mutations may mediate primary resistance and an escape mechanism from anti-EGFR receptor treatment [35].

Since extracellular signal-regulated kinases (ERKs) control the biological outcomes of EGFR/RAS signaling [36], we analyzed their activation status in organoid cultures. Interestingly, the presence of *KRAS/NRAS* mutations did not robustly coincide with MAPK pathway activation determined by the enhanced steady-state phosphorylation of effector kinases BRAF, CRAF, MEK1/2, ERK1/2, or RSK1 p90. Consequently, the wild-type status of *KRAS* or *NRAS* proteins did not predict gefitinib response. Similarly, monitoring the activation status of the MAPK pathway downstream of RAS did not substitute as a diagnostic approach for predicting treatment response. For example, *KRAS*^{G12S} organoid OT161 exhibiting low pathway activation, reminiscent of a “functionally wild-type” status, was gefitinib-resistant. Conversely, *KRAS/NRAS/BRAF*^{wt} culture OT299 exhibited a “functionally mutated,” highly active pathway status in spite of its susceptibility to gefitinib and other EGFR inhibitors. The polyclonal nature of organoids analyzed in early passage most likely reflects the intrinsic molecular heterogeneity of the donor tumor and may even preclude the detection of homogeneously strong MAPK activation. Eventually, subcloning of organoid cultures may allow enrichment of cells exhibiting uniform pathway activation in the presence of the corresponding upstream mutations. However, the value of cloned organoids for serving as avatars for the donor tumor will be diminished, since ITH is no longer maintained. The uncoupling of mutational *KRAS* status and pathway activation is not unprecedented, as shown in pancreatic adenocarcinoma and colorectal cancer [37, 38]. *BRAF*^{V600E} mutant colorectal cancers have been shown to express differential activation of the *KRAS/AKT* pathway and cell cycle proteins, indicating a diverse biology for a subtype of colorectal cancers even driven by the same driver mutation [39]. Here we show that MAPK signaling activity is diverse and not directly affected by the presence of a *KRAS* mutation. Hence, the true biology of these tumors may only be understood after conducting further comprehensive mechanistic studies. MAPK pathway activation is known to be modulated by dual-specificity phosphatase 6 (DUSP6) and Sprouty (SPRY) isoforms, which constitute transcriptional feedback loops and exert post-translational functions that constrain signaling-kinase activities [40–42]. However, the protein levels of DUSP6 and SPRY1, 2, and 3 were not correlated with MAPK activation in our organoid cultures.

Drug susceptibility testing was done in polyclonal organoids in low passage early after establishment of cultures. It is very likely that tumor subpopulations present in newly established models exhibit different degrees of fitness and pathway activity, a diverse potential to

expand, and non-homogenous inhibitor responses. In general, the big-bang hypothesis [20] predicts that during tumor evolution, many subpopulations exhibiting diverse mutation patterns, phenotypes, and treatment responses can emerge. Variable clonal population dynamics can substantially modulate treatment response and tolerance [43]. We investigated this scenario through multi-region sampling from a single colorectal tumor and established sibling organoids. Molecular analysis by sequencing crucial cancer genes, exomes, RNA, and targeted proteomics identified uniform *KRAS*, *TP53*, and *PIK3CA* driver gene mutations in all parallel cultures, but also provided evidence for substantial ITH. Not surprisingly, the sibling cultures showed profound differences in treatment response. Organoid culture R4 responded to 7 out of 10 inhibitors *in vitro*, while R1, harboring an additional *SMAD4* loss-of-function mutation, was resistant to all small molecules tested, except for regorafenib and sorafenib. The response pattern was unequal in R2 organoids despite sharing the *SMAD4* mutation and overall RNA expression pattern. The proliferation potential of R1 and R4 organoids *in vivo* differed substantially in spite of common *KRAS*^{G12D}, *PIK3CA*^{H1047R}, and *TP53*^{C242F} mutations. During the cetuximab/trametinib treatment cycle in xenografts, R4 cells survived and later formed the majority of the tumor post-therapy. The role of high ERK activation in R4 cells is not clear. High ERK activation does not necessarily drive proliferation, but it can be growth-inhibitory [44, 45].

The homozygous *SMAD4*^{R361H} mutation was not detectable in the bulk tumor CC0514. We assume that acquisition of the mutation was not due to a *de novo* event in culture, but rather was present in a minor subpopulation of the original tumor. The loss of *SMAD4* function, known to trigger tumor progression and metastasis [46–48], may explain the high proliferative potential of R1 organoids. In contrast, R4 organoids express presumably growth-inhibitory levels of phosphorylated ERK and resemble a cancer stem cell or progenitor phenotype, as described in Blaj *et al.* [38]. Interestingly, *SMAD4* proteins can be degraded via ERK1/2 signaling [49], suggesting that *SMAD4* does not function normally, even in poorly proliferative R4 organoids.

In summary, our findings imply that the administration of therapeutics to bulk organoid cultures may fall short of correctly displaying the functional diversity of existing subpopulations, due to heterogeneities of their genomes and transcriptomes. The great challenge of interpreting and reconciling multi-omics and response data in apparently closely “related” tumor cells was recently demonstrated by Roerink and colleagues [50]. The authors investigated organoid cultures established from single cell clones of different tumor areas of colorectal cancer patients. Via genomic sequencing, methylome analysis and RNA sequencing, they reconstructed evolutionary trees with high concordance between (epi)genomics and gene expression data. Yet, drug response in different organoids from the same tumor displayed substantial differences in IC₅₀ values of up to 1,000-fold for chemotherapeutic agents and targeted inhibitors. The molecular events that lead to differential drug sensitivity of closely related organoids from the same tumors are currently unknown.

In future diagnostics settings, multisampling of malignant tissues, drug sensitivity testing in culture and the depth of subsequent molecular analysis will have to be carefully balanced under consideration of sample availability, time and even funding constraints. The molecular analysis of organoid cultures in this study was limited by the focus on frequent oncogenes and tumor suppressor genes as well as by the availability of validated antibodies used in DigiWest assays. Notwithstanding such limitations, analyzing the dynamics of sibling cultures may help to overcome the limitations of predicting precision targeting of mutations retrieved by genomic analysis alone [51] and to better inform therapeutic decision-making.

Materials & methods

Ethics statement

EPO strictly follows the EU guideline European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (EST 123) and the German Animal Welfare Act (revised version Art. 3 G v. 28.7.2014 I 1308). Furthermore, we handle our animals according to the Regulation on the Protection of Animals Used for Experimental or for Other Scientific Purposes (Tierschutz-Versuchstierverordnung- TierSchVersV: revised version Art. 6 V v. 12.12.2013 I 4145). Compliance with the above rules and regulations is monitored by the Landesamt für Gesundheit und Soziales (LAGESo), which is the responsible regulatory authority monitoring animal husbandry.

Generation and propagation of organoid cell cultures

Organoid cultures were generated and propagated as previously described [11, 52]. Overall, 86 patient-derived three dimensional (PD3D) cell cultures were generated, including five samples that were isolated from mouse xenografts (PDX) and one sample that underwent transient engraftment and was then reintroduced into an *in vitro* organoid culture (OT151-PDX-PD3D). Additionally, for patient CC0514 we generated five organoid cultures from five separate regions of the primary tumor. The full cohort is described in [S1 Table](#).

Immunocharacterization

Two μm de-paraffinized FFPE tissue sections of donor tumors or organoid cultures grown for five days were stained using the primary antibodies anti-CK7 (clone OV-TL12/30, Dako, Germany), anti-CK20 (clone KS20.8, Dako), anti-CDX2 (clone CDX2-88, BioGenex, U.S.A.), and anti-KI67 (clone MIB-1, Dako) for 32 min at 37°C, using the ultraView DAB detection kit (Ventana, U.S.A.) on the BenchMark XT instrument (Ventana), as recommended by the manufacturer. Counterstaining was performed with Hematoxylin II Counterstain and Bluing Reagent (Ventana) for 4 min. Microscopy was performed with a Zeiss Axiovert 400 microscope (Zeiss, Germany).

For immunofluorescence imaging, organoid cultures were fixed in 4% paraformaldehyde for 30 min at room temperature and permeabilized with 0.1% Triton X-100 for 30 min. Samples were blocked in phosphate-buffered saline (PBS) with 10% bovine serum albumin (BSA) and incubated with primary antibodies overnight at 4°C. Antibodies used were Anti-Ezrin (clone EP886Y, Abcam, diluted 1:200) and EPCAM (VU1D9, Cell Signaling Technology, diluted 1:500). Samples were stained overnight with a conjugated secondary antibody at 4°C. F-actin was stained with Alexa Fluor 647 Phalloidin (#A22287, Thermo Fisher, diluted 1:20) for 30 min at room temperature. Nuclei were counterstained with DAPI (Sigma Aldrich). Cells were then transferred to microscope slides for examination using a Zeiss LSM 700 laser scanning microscope.

Nucleic acid preparation

Genomic DNA from organoid cultures and fresh tumor tissues was prepared using the AllPrep DNA/RNA Kit (QIAGEN, Germany) according to the manufacturer's protocols, and it was quantified using a Qubit 2.0 Fluorometer and the appropriate assay kits (Life Technologies, Germany). Genomic DNA from FFPE material from at least three consecutive 10 μm sections was isolated using the QIAGEN QIAamp DNA FFPE Tissue Kit to obtain sufficient amounts for targeted panel sequencing. The yields of FFPE-derived DNA were quantified with the TaqMan RNase P detection assay (Life Technologies).

Targeted deep sequencing and microsatellite status

Targeted sequencing was performed on an IonTorrent PGM bench-top sequencer (Life Technologies). Ten nanograms of genomic DNA were used to prepare Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies) amplicon libraries in conjunction with the Ion AmpliSeq Library Kit 2.0 (Life Technologies). For multiplexing purposes, unique Ion Xpress barcode adapters were assigned to every sample. For amplification, 17 or 20 PCR cycles were applied for cell-culture-based and FFPE-tissue-based samples, respectively. Amplicon libraries were quantified with the Ion Library Quantitation Kit (Life Technologies), diluted to 100 pM, and pooled in an equimolar concentration. Clonal amplification of single PCR templates was carried out on an Ion OneTouch 1 cycler in conjunction with the Ion OneTouch 200 Template Kit v2 DL. Sequencing of four to five pooled libraries was performed using Ion 316v2 sequencing chips. Base calling, read mapping, and coverage analysis were performed with the default settings of Torrent Suite software version 4.0.2. Targeted panel sequencing yielded over 44.0×10^6 mapped reads, and the oversampling rates averaged to 3.6×10^3 -fold. The mean uniformity of coverage (i.e., the distribution of reads across all 207 pooled PCR products per sample) was above 98%. Primary data analysis and variant calling were performed with the built-in Variant Caller tool (version v4.0-r76860), set to the “somatic, high stringency” option and down-sampling to 2,000 reads. Variant calls were visually inspected using the Integrated Genomics Viewer (IGV) [53] and annotated in accordance with HGVS recommendations [54]. To assess the effect of the retrieved mutations, the prediction tools SIFT [55], PolyPhen2 [56], and MutationTaster2 [57] were used. Visualization of mutations was carried out using the R Script ComplexHeatmap [58].

Additional Sanger sequencing was performed for sibling cultures CC0514-R1, CC0514-R2, and CC0514-R5 as early as six weeks post-culture initiation (S5 Fig), confirming the panel-sequencing results found for regions R1 and R2 (both *SMAD4*^{R361H}) and R5 (*SMAD4*^{wt}).

We also compared the mutation information gathered via panel sequencing with whole genome and whole exome data generated for the recently published study by Schuette *et al.* [11]. For an overlap of 40 organoid cultures for both methods and overlapping genes, 78% (103/132) of the mutations were covered by the targeted sequencing approach, while 22% (29/133) of the mutations found with exome sequencing were not covered by the panel's PCR amplicons (S13 Table). These included mutations in *APC* (86%, 25/29), *PIK3CA* (2/29), *TP53*, and *PTEN* (1/29 each). Microsatellite status was analyzed as previously described [11, 59].

Semi-automated high-throughput drug response assays

To perform systematic and parallel testing of drug responses *in vitro*, the organoid culture system was adapted to a 384-well microtiter plate format, as shown earlier [60]. In short, the assay system is based on a luminescence readout of cell viability, measured via ATP consumption. The population doubling time was determined by time-course based measurements using CellTiter-Glo luminescent cell viability assessment. Treatment duration covered two doubling times of the individual cultures, and small molecules were tested at concentrations ranging from 3.0 nM up to 60.0 μ M (assay cutoff), as previously shown [11]. Treatment duration of organoid sibling cultures derived from patient CC0514 was uniformly 72 h (S4 Table). The half-maximal inhibitory concentration of a compound determined *in vitro* (IC_{50}) is a measure of the potency of the compound in blocking cell growth and survival. To assess the potential clinical relevance of the drug response assays, we compared the relative IC_{50} values determined *in vitro* for 43 organoid cultures (S4 Table) with steady-state plasma concentrations (c_{ss}) of the therapeutic compounds achievable in patients (S3 Table). We used reference data obtained from publications or the investigator's brochures (IB) available at clinical-trial centers. For

compounds that have not yet entered late-phase clinical studies, we deduced c_{ss} values from *in vivo* mouse studies (BI-860585) or early (phase I) clinical studies (alpelisib, ravoxertinib). In addition, we determined the maximum inhibition (efficacy, E_{max} (%)) per drug per organoid culture model.

Whole transcriptome sequencing (RNAseq)

RNA from all organoid sibling cultures of patient CC0514 was extracted and quantified as described above. Whole transcriptome sequencing was performed at the Genomics and Proteomics Core Facility (GPCF) of the German Cancer Research Center (DKFZ). An average of 2 μ g total RNA per sample was used to generate barcode-labeled libraries using the Illumina TruSeq RNA sample preparation kit (Illumina, San Diego, CA, U.S.A.). Sequencing of 125 bp paired-end reads was performed on an Illumina HiSeq2000 sequencer with equal distribution of pooled libraries over two sequencing lanes. Mapping to the GRCh37 genome was performed with a STAR aligner [61], allowing maximally two mismatches/alignment gaps and 0.3% total mismatches per alignment. On average, RNAseq yielded 5.1×10^7 mapped reads (95% unique) covering 5.9 GB coding bases. Reads covering exonic regions per gene ID were counted using HTseq [62]. Downstream analysis was performed using AnnotationDBi, DESeq2 [63], limma [64–66], ggplot2 [67], and GSEA [68].

Whole exome sequencing (WES)

In total, 11 WES samples were processed, including a blood sample, five separate primary tumor regions from CC0514, and their respective organoid sibling culture derivatives. Whole exome sequencing was performed by the Genomics and Proteomics Core Facility (GPCF) at the German Cancer Research Center (DKFZ). The Agilent SureSelectXT Human All Exon V5 kit was used to generate 125 bp paired-end libraries subsequently sequenced on an Illumina HiSeq2000. The WES pipeline was organized as follows: First, poor-quality reads were filtered out using Trimmomatic [69], and the remaining reads were mapped to the GRCh37 (hg19) human reference genome using the BWA aligner [70]. Afterwards, the Genome Analysis Toolkit [71] was employed for duplicate removal, indel realignment, and base-quality recalibration. On average, 9.5×10^7 reads were uniquely mapped to the reference genome. We called germline, somatic, and loss of heterozygosity (LOH) mutations using the blood sample as reference with VarScan2 [72]. The minimum coverage for calling variant reads was set to 8 and minimum variant frequency to 0.09. We set tumor purity to 0.5 and minimum tumor frequency to 0.09. Rare SNP and indel mutations were selected as exonic, non-synonymous mutations with an ExAC [73] MAF score below 0.001. Evolutionary trees were built on all somatic mutations in exonic regions for cultures R1–R5. A neighbor-joining algorithm [74], implemented in the “APE” R package [75], was used on the Euclidean distance matrix generated from the binary mutation matrix. We used an artificial null-mutated control as root of the tree. In case of very low tumor cellularity, exome sequencing identified fewer somatic mutations (e.g., in tumor CC0514-R4). Following high-coverage panel sequencing, low-frequency mutations were detected after manually inspecting the sequencing reads (see mutation frequencies for CC0514-R4 tissue in [S2 Table](#)).

DigiWest multiplex protein profiling

Tissue samples and organoid cultures were subjected to multiplex protein profiling analysis of up to 150 (phospho-)proteins. In addition, three organoid cultures were subjected to drug treatment prior to protein extraction. For this, 2.4×10^5 cells ($= 4 \times 10^4$ cells/well in 6 wells total) per condition were plated, followed by a growth period of 72h and subsequent treatment

with gefitinib, afatinib, sapitinib and vehicle control (0.03% DMSO) for the duration of 72h. Drug concentrations were chosen based on clinically achievable plasma concentrations (c_{ss} , [S3 Table](#)). In order to monitor the pathway activity status and to gather a sufficient amount of cells for subsequent DigiWest analysis after drug treatment, IC_{50} values were selected for the gefitinib treatment of OT276 ($IC_{50} = 0.35 \mu\text{M}$ versus $c_{ss} = 1.04 \mu\text{M}$) and sapitinib treatment of OT347-M01 ($IC_{50} = 0.20 \mu\text{M}$ versus $c_{ss} = 1.52 \mu\text{M}$). After treatment, collected organoids were washed with ice cold PBS, sedimented, treated with Cell recovery solution (Corning) on ice for 30 min, washed twice with ice cold PBS, pelleted and snap frozen at -80°C until cell lysis.

The NuPAGE SDS-PAGE gel system (Life Technologies) was used to separate cellular lysates and blotting. Proteins (20 μg per sample) were fractionated by electrophoresis through 4–12% Bis-Tris gels according to the manufacturer's instructions. Blotting onto PVDF membranes (Millipore) was performed under standard conditions. For high-content western analysis, the DigiWest procedure was performed as previously described [24]. Briefly, proteins immobilized on the blotting membrane were biotinylated (NHS-PEG12-Biotin, Thermo Scientific), and individual sample lanes were cut into a comb-like structure (strip height = 0.5 mm each, strip width = 6 mm) using an electronic cutting tool (Silhouette SD). The resulting 96 strips corresponded to 96 molecular weight fractions immobilized on individual membrane strips; they covered a range from 15 kDa to 250 kDa.

For protein elution, individual strips were placed in separate wells of a 96-well plate and incubated for 2 hours in 10 μl elution buffer (8 M urea, 1% Triton-X100 in 100 mM Tris-HCl, pH 9.5) for solubilization. After adding 90 μl of dilution buffer (5% BSA in PBS, 0.02% sodium azide, 0.05% Tween-20), 96 different Neutravidin-coated Luminex bead sets (60,000 beads/well) were added to the individual wells, and biotinylated proteins were captured on the bead surface. After overnight incubation, the Luminex beads were pooled, washed, and stored in a storage buffer (1% BSA, 0.05% Tween-20, 0.05% sodium azide in PBS) at 4°C . For antibody incubation, an aliquot of the bead pool (approximately 0.3% of the available bead pool) was transferred into an assay plate, and 30 μl of diluted western blot antibody in assay buffer (Blocking Reagent [Roche Applied Science], 0.05% Tween 20, 0.02% sodium azide, and 0.2% milk powder) was added per well. The list of antibodies is shown in [S5 and S6 Tables](#). One hundred fifty-four antibody incubations were performed overnight at 4°C for each protein sample. For visualization, the beads were washed twice with 100 μl of PBST before species-specific PE-labeled secondary antibody (Jackson Dianova) was added in 30 μl of assay buffer for 1 hour. After two washes with 100 μl of PBST, analyte signals were generated in a FlexMAP 3D instrument (Luminex).

Data analysis: Data generated by the Luminex instrument were analyzed using a proprietary analysis tool that visualizes the fluorescent signals as bar graphs and identifies specific protein peaks detected by antibodies. Each graph was composed of the 96 values derived from the corresponding molecular mass fractions obtained after antibody incubation. The software tool identified specific peaks, and a relative molecular mass was assigned to each of the 96 fractions. After background correction, specific signal intensities were calculated as the integral of the identified peak.

***In vivo* drug response assays and FACS analysis**

Cell cultures CC0514-R1 and CC0514-R4 were transduced with lentiviruses carrying a phosphoglycerate kinase (PGK) promoter controlled eGFP (pLenti PGK GFP Puro, w509-5, Addgene) or mCherry. The pLenti PGK mCherry Puro vector construct was created via PCR cloning of mCherry cDNA from plasmid vector 7TCF (Addgene, Plasmid #24307) and modified with BamHI and BsrGI restriction sites for directed ligation into plasmid vector pLenti

PGFK GFP Puro. Plasmids were tested for correct insert orientation via Sanger sequencing. Transduced cells were selected with puromycin. Following organoid cell culture expansion, cells were harvested at passage 08, digested, and filtered, and single cells were counted. Transplantation into nude mice was achieved by subcutaneous injection of single populations or 1:1 mixtures of 1.0×10^6 cells each at EPO GmbH (Experimental Pharmacology and Oncology, Berlin-Buch, Germany). Mice (BOMTac: NMRI-Foxn1^{nu}; Genotype NMRI NU-F Sp/Sp) were obtained commercially from Taconic (Lille Skensved, DK).

Organoid models were injected at 1:1 dilution with Matrigel (Corning, NL) and were allowed to expand for 10 days, reaching PDX sizes of 0.1 cm^3 , before treatment with selected compounds for 36 days. The compounds were administered either orally or intraperitoneally. Following the first day of treatment, the tumor volume and body weight were recorded twice weekly. Animal welfare was controlled regularly. Animals in poor health were sacrificed independent of treatment duration. Tumor volume was calculated from the measurement of the length and width of subcutaneous tumors ($TV = (\text{length} + \text{width})^2 / 2$). For further information on the handling of PDX models, please refer to [76]. Mice were sacrificed after the PDX tumors reached a size of approximately 1.5 cm^3 . Retrieved PDX tumors were subjected to whole-mount (immunofluorescence) imaging using a Zeiss Axiovert 400 microscope (Zeiss, Germany). PDX tumor tissues were digested to produce single-cell suspensions and analyzed by FACS at the German Rheumatism Research Centre (DRFZ, Berlin, Germany) to record the distribution of GFP- and mCherry-positive cells.

Supporting information

S1 Fig. Culture establishment statistics and UICC stages of donor tumors. Bar graph shows culture establishment percentages per UICC stage.
(TIF)

S2 Fig. Bead-based western blot analysis of (phospho-) proteins in 9 PD3D cultures reveals sample-specific protein expression levels. Bead-based western blotting (“DigiWest”) analysis of 104 (phospho-) proteins in 9 organoid cultures and tissues (healthy and tumor). The hierarchical cluster analysis shows scaled, Strep-normalized protein expression values, color-coded from lowest (yellow) to highest (blue) expression value.
(TIF)

S3 Fig. DigiWest protein expression profiles of organoids OT151, OT276 and OT347-M01 treated with gefitinib, afatinib and sapitinib. Protein expression profiling of cultured organoids derived from three different patients was performed using DigiWest and expression of 135 proteins was measured using specific antibodies. Measurements were performed on organoids that were treated for 72h with the RTK inhibitors gefitinib, afatinib and sapitinib and with vehicle control (DMSO). To visualize the effect of the different substances the ratio of the specific RTK inhibitor over the vehicle control was calculated, log₂ transformed and the data was subjected to hierarchical cluster analysis (Pearson Correlation, complete linkage).
(TIF)

S4 Fig. *In vivo* drug response assay for mixed subpopulations of sibling cultures CC0514-R1- and -R4. *In vivo* drug treatment of 1:1 mixed cells (1.0×10^6 overall) of cultures CC0514-R1-GFP and CC0514-R4-mCh started 10 days post injection. Drug treatment was stopped at day 45. Line plot shows growth curves of triplicates of the respective single or combinatorial treatments. Color code is given in the legend.
(TIF)

S5 Fig. Sanger sequencing of SMAD4 codon 361 in patient CC0514. Electropherograms of SMAD4 codon 361 affected by SMAD4 mutations in cultures CC0514-R1 and -R2 in comparison to SMAD4 wild-type culture CC0514-R5. For all cases, one early and later passage was tested. Blue areas indicate the respective codon, read from left to right.

(TIF)

S1 Table. Description of study cohort.

(XLSX)

S2 Table. Panel sequencing results for 49 PD3D cultures and 29 matched tumor tissues.

(XLSX)

S3 Table. Compound c_{ss} values for *in vitro* assay.

(XLSX)

S4 Table. IC_{50} - and E_{max} values of tested PD3D cultures.

(XLSX)

S5 Table. DigiWest assay results for tissues and organoid cultures.

(XLSX)

S6 Table. DigiWest assay results for organoids treated with gefitinib, afatinib and sapitinib.

(XLSX)

S7 Table. Consensus molecular subtypes (CMS) of CC0514 sibling cultures.

(XLSX)

S8 Table. Somatic mutations in patient CC0514 tumor tissues and *in vitro* cultures.

(XLSX)

S9 Table. Differentially expressed genes of CC0514 sibling cultures grouped by SMAD4 mutation status (R1, R2 vs. R3, R4, R5).

(XLSX)

S10 Table. PDX tumor volumes of single and mixed populations of CC0514-R1 and -R4 cells.

(XLSX)

S11 Table. PDX tumor volumes of treated mixed populations of CC0514-R1-GFP and CC0514-R4-mCh cells.

(XLSX)

S12 Table. FACS results—GFP⁺/mCherry⁺ fractions and fold enrichment.

(XLSX)

S13 Table. Panel sequencing results compared to whole exome/genome data from [11].

(XLSX)

Acknowledgments

We thank Boehringer Ingelheim for kindly providing the compounds BI-585860 and afatinib for the *in vitro* and *in vivo* experiments. We also thank the members of the OncoTrack consortium for their support and fruitful discussions, especially Pilar Garin-Chesa, Martin Lange, Joseph Regan, Christoph Reinhard, and Juan A. Velasco.

We thank the surgeons, clinical investigators, and technical assistants from Graz (Stefan Uranitsch, Nicole Golob, Caroline Schweiger), Berlin (Hendrik Bläker, Floria Roßner, Annika Nonnenmacher, Inge Schwarzenau), Bonn (Sonja Schäfer), and Cologne (Reinhard Büttner) for providing the samples and relevant clinical data. We thank the scientists and technical assistants from Charité (Yvonne Welte, Cathrin Davies, Dorothea Pryzbilla), Eli Lilly and Company (Laura Alvaro-Espinosa, José Luis Díaz-Puentes, María José Lallena, Christoph Reinhard), NMI (Simon Kling) and NMI TT Pharmaservices (Anja Briese, Przemyslaw Dudys) for technical assistance and fruitful discussions. The authors greatly acknowledge the team of the Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany for their sequencing service.

Author Contributions

Conceptualization: Ulrich Keilholz, Reinhold Schäfer, Christian R. A. Regenbrecht.

Data curation: Dirk Schumacher, Geoffroy Andrieux, Karsten Boehnke, Jens Hoffmann, Melanie Boerries.

Formal analysis: Dirk Schumacher, Geoffroy Andrieux, Karsten Boehnke, Marlen Keil, Alessandra Silvestri, Johannes Haybaeck, Gerrit Erdmann, Christoph Sachse, Markus Templin, Jens Hoffmann, Melanie Boerries, Reinhold Schäfer, Christian R. A. Regenbrecht.

Funding acquisition: Ulrich Keilholz, Jens Hoffmann, Reinhold Schäfer, Christian R. A. Regenbrecht.

Investigation: Dirk Schumacher, Geoffroy Andrieux, Karsten Boehnke, Marlen Keil, Alessandra Silvestri, Maxine Silvestrov, Christoph Sachse, Reinhold Schäfer, Christian R. A. Regenbrecht.

Methodology: Dirk Schumacher, Karsten Boehnke, Ulrich Keilholz, Reinhold Schäfer, Christian R. A. Regenbrecht.

Project administration: Reinhold Schäfer, Christian R. A. Regenbrecht.

Resources: Markus Templin, Jens Hoffmann, Reinhold Schäfer, Christian R. A. Regenbrecht.

Software: Geoffroy Andrieux, Gerrit Erdmann, Christoph Sachse, Melanie Boerries.

Supervision: Ulrich Keilholz, Markus Templin, Melanie Boerries.

Validation: Karsten Boehnke, Johannes Haybaeck, Christoph Sachse.

Visualization: Dirk Schumacher, Geoffroy Andrieux, Gerrit Erdmann, Christoph Sachse, Markus Templin, Melanie Boerries, Reinhold Schäfer, Christian R. A. Regenbrecht.

Writing – original draft: Dirk Schumacher, Karsten Boehnke, Reinhold Schäfer, Christian R. A. Regenbrecht.

Writing – review & editing: Dirk Schumacher, Geoffroy Andrieux, Karsten Boehnke, Marlen Keil, Alessandra Silvestri, Ulrich Keilholz, Johannes Haybaeck, Gerrit Erdmann, Christoph Sachse, Markus Templin, Jens Hoffmann, Melanie Boerries, Reinhold Schäfer, Christian R. A. Regenbrecht.

References

1. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. *Nature*. 2012; 487(7407):330–7. <https://doi.org/10.1038/nature11252> PMID: 22810696; PubMed Central PMCID: PMC3401966.

2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell*. 1990; 61(5):759–67. PMID: [2188735](#).
3. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. *Nature medicine*. 2015; 21(11):1350–6. <https://doi.org/10.1038/nm.3967> PMID: [26457759](#); PubMed Central PMCID: [PMCPMC4636487](#).
4. Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. *Nature reviews Cancer*. 2017; 17(2):79–92. <https://doi.org/10.1038/nrc.2016.126> PMID: [28050011](#).
5. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *The New England journal of medicine*. 2013; 369(11):1023–34. <https://doi.org/10.1056/NEJMoa1305275> PMID: [24024839](#).
6. Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. *Nat Rev Clin Oncol*. 2017; 14(4):235–46. <https://doi.org/10.1038/nrclinonc.2016.171> PMID: [27922044](#).
7. Simian M, Bissell MJ. Organoids: A historical perspective of thinking in three dimensions. *The Journal of cell biology*. 2017; 216(1):31–40. <https://doi.org/10.1083/jcb.201610056> PMID: [28031422](#); PubMed Central PMCID: [PMCPMC5223613](#).
8. Ashley N, Jones M, Ouaret D, Wilding J, Bodmer WF. Rapidly derived colorectal cancer cultures recapitulate parental cancer characteristics and enable personalized therapeutic assays. *The Journal of pathology*. 2014; 234(1):34–45. <https://doi.org/10.1002/path.4371> PMID: [24797403](#).
9. van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. *Cell*. 2015; 161(4):933–45. <https://doi.org/10.1016/j.cell.2015.03.053> PMID: [25957691](#).
10. Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, et al. Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. *Cancer Discov*. 2017; 7(5):462–77. <https://doi.org/10.1158/2159-8290.CD-16-1154> PMID: [28331002](#); PubMed Central PMCID: [PMCPMC5413423](#).
11. Schutte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D, Keil M, et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. *Nat Commun*. 2017; 8:14262. <https://doi.org/10.1038/ncomms14262> PMID: [28186126](#).
12. Linnekamp JF, Hooff SRV, Prasetyanti PR, Kandimalla R, Buikhuisen JY, Fessler E, et al. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. *Cell Death Differ*. 2018. <https://doi.org/10.1038/s41418-017-0011-5> PMID: [29305587](#).
13. Regan JL, Schumacher D, Staudte S, Steffen A, Haybaeck J, Keilholz U, et al. Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells. *Cell Rep*. 2017; 21(10):2813–28. <https://doi.org/10.1016/j.celrep.2017.11.025> PMID: [29212028](#).
14. Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. *Science*. 2018; 359(6378):920–6. <https://doi.org/10.1126/science.aao2774> PMID: [29472484](#).
15. Verissimo CS, Overmeer RM, Ponsioen B, Drost J, Mertens S, Verlaan-Klink I, et al. Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. *Elife*. 2016; 5. <https://doi.org/10.7554/eLife.18489> PMID: [27845624](#); PubMed Central PMCID: [PMCPMC5127645](#).
16. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. *Nature*. 2013; 501(7467):355–64. <https://doi.org/10.1038/nature12627> PMID: [24048068](#).
17. Russo M, Siravegna G, Blazskowsky LS, Corti G, Crisafulli G, Ahronian LG, et al. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. *Cancer Discov*. 2016; 6(2):147–53. <https://doi.org/10.1158/2159-8290.CD-15-1283> PMID: [26644315](#); PubMed Central PMCID: [PMCPMC4744519](#).
18. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *The New England journal of medicine*. 2012; 366(10):883–92. <https://doi.org/10.1056/NEJMoa1113205> PMID: [22397650](#).
19. Mamlouk S, Childs LH, Aust D, Heim D, Melching F, Oliveira C, et al. DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. *Nat Commun*. 2017; 8:14093. <https://doi.org/10.1038/ncomms14093> PMID: [28120820](#); PubMed Central PMCID: [PMCPMC5288500](#).
20. Sottoriva A, Kang H, Ma Z, Graham TA, Salomon MP, Zhao J, et al. A Big Bang model of human colorectal tumor growth. *Nature genetics*. 2015; 47(3):209–16. <https://doi.org/10.1038/ng.3214> PMID: [25665006](#); PubMed Central PMCID: [PMCPMC4575589](#).
21. Bozic I, Nowak MA. Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. *Proceedings of the National Academy of Sciences of the United States of America*.

- 2014; 111(45):15964–8. <https://doi.org/10.1073/pnas.1412075111> PMID: 25349424; PubMed Central PMCID: PMC4234551.
22. Chang F, Li MM. Clinical application of amplicon-based next-generation sequencing in cancer. *Cancer Genet.* 2013; 206(12):413–9. <https://doi.org/10.1016/j.cancergen.2013.10.003> PMID: 24332266.
 23. Misyura M, Zhang T, Sukhai MA, Thomas M, Garg S, Kamel-Reid S, et al. Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics. *J Mol Diagn.* 2016; 18(6):842–50. <https://doi.org/10.1016/j.jmoldx.2016.06.004> PMID: 27770852.
 24. Treindl F, Ruprecht B, Beiter Y, Schultz S, Dottinger A, Staebler A, et al. A bead-based western for high-throughput cellular signal transduction analyses. *Nat Commun.* 2016; 7:12852. <https://doi.org/10.1038/ncomms12852> PMID: 27659302.
 25. Tsongalis GJ, Peterson JD, de Abreu FB, Tunkey CD, Gallagher TL, Strausbaugh LD, et al. Routine use of the Ion Torrent AmpliSeq Cancer Hotspot Panel for identification of clinically actionable somatic mutations. *Clinical chemistry and laboratory medicine: CCLM / FESCC.* 2014; 52(5):707–14. <https://doi.org/10.1515/cclm-2013-0883> PMID: 24334431.
 26. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. *Clinical Cancer Research.* 2002; 8(5):994–1003. PMID: 12006511.
 27. Bull Phelps SL, Schorge JO, Peyton MJ, Shigematsu H, Xiang LL, Miller DS, et al. Implications of EGFR inhibition in ovarian cancer cell proliferation. *Gynecol Oncol.* 2008; 109(3):411–7. <https://doi.org/10.1016/j.ygyno.2008.02.030> PMID: 18423824.
 28. Ashraf SQ, Nicholls AM, Wilding JL, Ntourophi TG, Mortensen NJ, Bodmer WF. Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. *Proceedings of the National Academy of Sciences of the United States of America.* 2012; 109(51):21046–51. <https://doi.org/10.1073/pnas.1218750110> PMID: 23213241; PubMed Central PMCID: PMC3529069.
 29. Holubec L, Polivka J Jr., Safanda M, Karas M, Liska V. The Role of Cetuximab in the Induction of Anti-cancer Immune Response in Colorectal Cancer Treatment. *Anticancer Res.* 2016; 36(9):4421–6. <https://doi.org/10.21873/anticancer.10985> PMID: 27630277.
 30. Wang L, Wei Y, Fang W, Lu C, Chen J, Cui G, et al. Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer. *Cell Physiol Biochem.* 2017; 44(3):1038–50. <https://doi.org/10.1159/000485404> PMID: 29179214.
 31. De Braud F, Machiels JP, Salvagni S, Rottey S, Cresta S, Mariani GL, et al. First in human study of BI860585 alone and in combination with exemestane or paclitaxel in patients with advanced solid tumors. *Targeted Anticancer Therapies (TAT) Congress; Mar 4–7; Washington D.C.* 2014.
 32. Wu JW, Fairman R, Penry J, Shi Y. Formation of a stable heterodimer between Smad2 and Smad4. *The Journal of biological chemistry.* 2001; 276(23):20688–94. <https://doi.org/10.1074/jbc.M100174200> PMID: 11274206.
 33. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. *Science translational medicine.* 2011; 3(99):99ra86. <https://doi.org/10.1126/scitransmed.3002442> PMID: 21900593; PubMed Central PMCID: PMC3268675.
 34. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. *Cancer Discov.* 2011; 1(6):508–23. <https://doi.org/10.1158/2159-8290.CD-11-0109> PMID: 22586653.
 35. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. *Cancer Discov.* 2013; 3(6):658–73. <https://doi.org/10.1158/2159-8290.CD-12-0558> PMID: 23729478; PubMed Central PMCID: PMC4078408.
 36. Eblen ST. Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes. *Adv Cancer Res.* 2018; 138:99–142. <https://doi.org/10.1016/bs.acr.2018.02.004> PMID: 29551131.
 37. Lemstrova R, Brynychova V, Hughes DJ, Hlavac V, Dvorak P, Doherty JE, et al. Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. *Oncol Lett.* 2017; 14(5):5980–8. <https://doi.org/10.3892/ol.2017.6946> PMID: 29113235; PubMed Central PMCID: PMC45661609.
 38. Blaj C, Schmidt EM, Lamprecht S, Hermeking H, Jung A, Kirchner T, et al. Oncogenic Effects of High MAPK Activity in Colorectal Cancer Mark Progenitor Cells and Persist Irrespective of RAS Mutations.

- Cancer research. 2017; 77(7):1763–74. <https://doi.org/10.1158/0008-5472.CAN-16-2821> PMID: 28202525.
39. Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, et al. BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression. *Clinical Cancer Research*. 2017; 23(1):104–15. <https://doi.org/10.1158/1078-0432.CCR-16-0140> PMID: 27354468.
 40. Bagnyukova TV, Restifo D, Beeharry N, Gabitova L, Li T, Serebriiskii IG, et al. DUSP6 regulates drug sensitivity by modulating DNA damage response. *British journal of cancer*. 2013; 109(4):1063–71. <https://doi.org/10.1038/bjc.2013.353> PMID: 23839489; PubMed Central PMCID: PMC3749559.
 41. Bluthgen N, Legewie S, Kielbasa SM, Schramme A, Tchernitsa O, Keil J, et al. A systems biological approach suggests that transcriptional feedback regulation by dual-specificity phosphatase 6 shapes extracellular signal-related kinase activity in RAS-transformed fibroblasts. *FEBS J*. 2009; 276(4):1024–35. <https://doi.org/10.1111/j.1742-4658.2008.06846.x> PMID: 19154344.
 42. Masoumi-Moghaddam S, Amini A, Morris DL. The developing story of Sprouty and cancer. *Cancer metastasis reviews*. 2014; 33(2–3):695–720. <https://doi.org/10.1007/s10555-014-9497-1> PMID: 24744103; PubMed Central PMCID: PMC4113681.
 43. Kreso A, O'Brien CA, van Galen P, Gan OI, Notta F, Brown AM, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. *Science*. 2013; 339(6119):543–8. <https://doi.org/10.1126/science.1227670> PMID: 23239622.
 44. Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. *Cell*. 2012; 149(2):307–21. <https://doi.org/10.1016/j.cell.2012.02.053> PMID: 22500798; PubMed Central PMCID: PMC3328787.
 45. Papke B, Der CJ. Drugging RAS: Know the enemy. *Science*. 2017; 355(6330):1158–63. <https://doi.org/10.1126/science.aam7622> PMID: 28302824.
 46. Alazzouzi H, Domingo E, Gonzalez S, Blanco I, Armengol M, Espin E, et al. Low levels of microsatellite instability characterize MLH1 and MSH2 HNPCC carriers before tumor diagnosis. *Hum Mol Genet*. 2005; 14(2):235–9. <https://doi.org/10.1093/hmg/ddi021> PMID: 15563510.
 47. Salovaara R, Roth S, Loukola A, Launonen V, Sistonen P, Avizienyte E, et al. Frequent loss of SMAD4/DPC4 protein in colorectal cancers. *Gut*. 2002; 51(1):56–9. PMID: 12077092; PubMed Central PMCID: PMC1773263.
 48. Yamamoto T, Kawada K, Itatani Y, Inamoto S, Okamura R, Iwamoto M, et al. Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-Associated Neutrophils through CCL15-CCR1 Axis. *Clinical Cancer Research*. 2017; 23(3):833–44. <https://doi.org/10.1158/1078-0432.CCR-16-0520> PMID: 27492974.
 49. Zhao M, Mishra L, Deng CX. The role of TGF-beta/SMAD4 signaling in cancer. *Int J Biol Sci*. 2018; 14(2):111–23. <https://doi.org/10.7150/ijbs.23230> PMID: 29483830; PubMed Central PMCID: PMC5821033.
 50. Roerink SF, Sasaki N, Lee-Six H, Young MD, Alexandrov LB, Behjati S, et al. Intra-tumour diversification in colorectal cancer at the single-cell level. *Nature*. 2018; 556(7702):457–62. <https://doi.org/10.1038/s41586-018-0024-3> PMID: 29643510.
 51. Brock A, Huang S. Precision Oncology: Between Vaguely Right and Precisely Wrong. *Cancer research*. 2017; 77(23):6473–9. <https://doi.org/10.1158/0008-5472.CAN-17-0448> PMID: 29162615.
 52. Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. *Gastroenterology*. 2011; 141(5):1762–72. <https://doi.org/10.1053/j.gastro.2011.07.050> PMID: 21889923.
 53. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Briefings in bioinformatics*. 2013; 14(2):178–92. <https://doi.org/10.1093/bib/bbs017> PMID: 22517427; PubMed Central PMCID: PMC3603213.
 54. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. *Human mutation*. 2000; 15(1):7–12. [https://doi.org/10.1002/\(SICI\)1098-1004\(200001\)15:1<7::AID-HUMU4>3.0.CO;2-N](https://doi.org/10.1002/(SICI)1098-1004(200001)15:1<7::AID-HUMU4>3.0.CO;2-N) PMID: 10612815.
 55. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nature protocols*. 2009; 4(7):1073–81. <https://doi.org/10.1038/nprot.2009.86> PMID: 19561590.
 56. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. *Nature methods*. 2010; 7(4):248–9. <https://doi.org/10.1038/nmeth0410-248> PMID: 20354512; PubMed Central PMCID: PMC2855889.

57. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. *Nature methods*. 2014; 11(4):361–2. <https://doi.org/10.1038/nmeth.2890> PMID: [24681721](https://pubmed.ncbi.nlm.nih.gov/24681721/).
58. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics*. 2016; 32(18):2847–9. <https://doi.org/10.1093/bioinformatics/btw313> PMID: [27207943](https://pubmed.ncbi.nlm.nih.gov/27207943/).
59. Goel A, Nagasaka T, Hamelin R, Boland CR. An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. *PloS one*. 2010; 5(2):e9393. <https://doi.org/10.1371/journal.pone.0009393> PMID: [20195377](https://pubmed.ncbi.nlm.nih.gov/20195377/); PubMed Central PMCID: [PMC2827558](https://pubmed.ncbi.nlm.nih.gov/PMC2827558/).
60. Boehnke K, Iversen PW, Schumacher D, Lallena MJ, Haro R, Amat J, et al. Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures. *Journal of biomolecular screening*. 2016; 21(9):931–41. <https://doi.org/10.1177/1087057116650965> PMID: [27233291](https://pubmed.ncbi.nlm.nih.gov/27233291/); PubMed Central PMCID: [PMC5030729](https://pubmed.ncbi.nlm.nih.gov/PMC5030729/).
61. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*. 2013; 29(1):15–21. <https://doi.org/10.1093/bioinformatics/bts635> PMID: [23104886](https://pubmed.ncbi.nlm.nih.gov/23104886/); PubMed Central PMCID: [PMC3530905](https://pubmed.ncbi.nlm.nih.gov/PMC3530905/).
62. Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics*. 2015; 31(2):166–9. <https://doi.org/10.1093/bioinformatics/btu638> PMID: [25260700](https://pubmed.ncbi.nlm.nih.gov/25260700/); PubMed Central PMCID: [PMC4287950](https://pubmed.ncbi.nlm.nih.gov/PMC4287950/).
63. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome biology*. 2014; 15(12):550. <https://doi.org/10.1186/s13059-014-0550-8> PMID: [25516281](https://pubmed.ncbi.nlm.nih.gov/25516281/); PubMed Central PMCID: [PMC4302049](https://pubmed.ncbi.nlm.nih.gov/PMC4302049/).
64. Liu R, Holik AZ, Su S, Jansz N, Chen K, Leong HS, et al. Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses. *Nucleic acids research*. 2015; 43(15):e97. <https://doi.org/10.1093/nar/gkv412> PMID: [25925576](https://pubmed.ncbi.nlm.nih.gov/25925576/); PubMed Central PMCID: [PMC4551905](https://pubmed.ncbi.nlm.nih.gov/PMC4551905/).
65. Phipson B, Lee S, Majewski IJ, Alexander WS, Smyth GK. Robust Hyperparameter Estimation Protects against Hypervariable Genes and Improves Power to Detect Differential Expression. *Ann Appl Stat*. 2016; 10(2):946–63. <https://doi.org/10.1214/16-AOAS920> PMID: [28367255](https://pubmed.ncbi.nlm.nih.gov/28367255/); PubMed Central PMCID: [PMC5373812](https://pubmed.ncbi.nlm.nih.gov/PMC5373812/).
66. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic acids research*. 2015; 43(7):e47. <https://doi.org/10.1093/nar/gkv007> PMID: [25605792](https://pubmed.ncbi.nlm.nih.gov/25605792/); PubMed Central PMCID: [PMC4402510](https://pubmed.ncbi.nlm.nih.gov/PMC4402510/).
67. Wickham H. ggplot2: Elegant Graphics for Data Analysis: Springer-Verlag New York; 2009.
68. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102(43):15545–50. <https://doi.org/10.1073/pnas.0506580102> PMID: [16199517](https://pubmed.ncbi.nlm.nih.gov/16199517/); PubMed Central PMCID: [PMC1239896](https://pubmed.ncbi.nlm.nih.gov/PMC1239896/).
69. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*. 2014; 30(15):2114–20. <https://doi.org/10.1093/bioinformatics/btu170> PMID: [24695404](https://pubmed.ncbi.nlm.nih.gov/24695404/); PubMed Central PMCID: [PMC4103590](https://pubmed.ncbi.nlm.nih.gov/PMC4103590/).
70. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics*. 2009; 25(14):1754–60. <https://doi.org/10.1093/bioinformatics/btp324> PMID: [19451168](https://pubmed.ncbi.nlm.nih.gov/19451168/); PubMed Central PMCID: [PMC2705234](https://pubmed.ncbi.nlm.nih.gov/PMC2705234/).
71. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res*. 2010; 20(9):1297–303. <https://doi.org/10.1101/gr.107524.110> PMID: [20644199](https://pubmed.ncbi.nlm.nih.gov/20644199/); PubMed Central PMCID: [PMC2928508](https://pubmed.ncbi.nlm.nih.gov/PMC2928508/).
72. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res*. 2012; 22(3):568–76. <https://doi.org/10.1101/gr.129684.111> PMID: [22300766](https://pubmed.ncbi.nlm.nih.gov/22300766/); PubMed Central PMCID: [PMC3290792](https://pubmed.ncbi.nlm.nih.gov/PMC3290792/).
73. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature*. 2016; 536(7616):285–91. <https://doi.org/10.1038/nature19057> PMID: [27535533](https://pubmed.ncbi.nlm.nih.gov/27535533/); PubMed Central PMCID: [PMC5018207](https://pubmed.ncbi.nlm.nih.gov/PMC5018207/).
74. Gascuel O. BIONJ: an improved version of the NJ algorithm based on a simple model of sequence data. *Mol Biol Evol*. 1997; 14(7):685–95. <https://doi.org/10.1093/oxfordjournals.molbev.a025808> PMID: [9254330](https://pubmed.ncbi.nlm.nih.gov/9254330/).
75. Paradis E, Claude J, Strimmer K. APE: Analyses of Phylogenetics and Evolution in R language. *Bioinformatics*. 2004; 20(2):289–90. PMID: [14734327](https://pubmed.ncbi.nlm.nih.gov/14734327/).

76. Rivera M, Keil M, Boehnke K, Lange M, Schumacher D, Schäfer R, et al. Generation of drug response data from 57 new patient-derived colon cancer xenografts and 3D cell cultures for systematic correlation with tumor biology within the OncoTrack* project [abstract]. 105th Annual Meeting of the American Association for Cancer Research; Apr 5–9; San Diego, CA: AACR; 2014.
77. Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, et al. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. *Science translational medicine*. 2012; 4(136):136ra70. <https://doi.org/10.1126/scitranslmed.3003513> PMID: [22649091](https://pubmed.ncbi.nlm.nih.gov/22649091/); PubMed Central PMCID: PMCPMC3836384.